Paper9242542
Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype.
Koene HR and 5 others. Blood, 1997. Cited by 676 papers, by iCite.
Cite this record
ConductScience Library. Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Papers, record 9242542. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/9242542
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype.
- PubMed
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Immunoglobulin G | Major topic |
| Killer Cells, Natural | Major topic |
| Receptors, IgG | Major topic |
| Alleles | |
| Antibodies, Monoclonal | |
| Genotype | |
| Humans | |
| Phenotype | |
| Polymorphism, Genetic | |
| Protein Binding |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT00590941 | Genetic Determinations for Side Effects and Response Rate for Patients Receiving Chemotherapy With Diffuse Large Cell Lymphoma | Background |
Source ClinicalTrials.gov
Cited by339
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 676 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42926294 | Analytical Assessment of Fc-Receptor Binding of Therapeutic IgG1 Antibodies: A Surface Plasmon Resonance Approach. | Methods Mol Biol | 2027 | https://conductscience.org/library/papers/42926294 | PubMed |
| 42889072 | Identification of a novel, expressed, alternatively spliced FCER1G protein that inhibits receptor function. | Front Immunol | 2026 | https://conductscience.org/library/papers/42889072 | PubMed |
| 42571998 | Rituximab Binding Endows CD20+ Extracellular Vesicles With NK Cell-Activating Properties in B Cell Lymphoma. | J Extracell Vesicles | 2026 | https://conductscience.org/library/papers/42571998 | PubMed |
| 42505378 | Next-Generation Multi-Engager Complexes Linking Natural Killer Cells to Tumor Cells and Targeting the Proteolytic Checkpoint ADAM17. | Cells | 2026 | https://conductscience.org/library/papers/42505378 | PubMed |
| 42410642 | ADAM17 blockade restores natural killer cell antibody-dependent cytotoxicity against human immunodeficiency virus-1. | Virol J | 2026 | https://conductscience.org/library/papers/42410642 | PubMed |
| 41992203 | FcγR-driven chimeric receptor T cells in cancer therapy: a novel frontier in antibody-guided immunotherapy. | Cancer Cell Int | 2026 | https://conductscience.org/library/papers/41992203 | PubMed |
| 41928770 | A new, glycoengineered form of anti-CD20 monoclonal antibody, in treatment of multiple sclerosis. | Ther Adv Neurol Disord | 2026 | https://conductscience.org/library/papers/41928770 | PubMed |
| 41912269 | HFB301001, an OX40-based immunotherapy, drives Treg clearance and CTL activation through optimized OX40 receptor clustering. | J Immunother Cancer | 2026 | https://conductscience.org/library/papers/41912269 | PubMed |
| 41827873 | Factors Influencing Immunotherapy Response in Neuroblastoma: From Tumor Microenvironment to Combination Strategies. | Cells | 2026 | https://conductscience.org/library/papers/41827873 | PubMed |
| 41694365 | Dual-functioning Targeted ADAM17 Blocker CD16 (TAB16) mediates selective ADAM17 inhibition in NK cells and engages overexpressed ADAM17 in tumor cells to induce cytotoxicity. | Front Immunol | 2026 | https://conductscience.org/library/papers/41694365 | PubMed |
| 41515926 | Rituximab in Connective Tissue Disease-Associated Interstitial Lung Disease: From Immunopathogenesis to Therapeutic Implications. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/41515926 | PubMed |
| 41219228 | A monoclonal antibody that inhibits the shedding of CD16a and CD16b and promotes antibody-dependent cellular cytotoxicity against tumors. | Nat Commun | 2025 | https://conductscience.org/library/papers/41219228 | PubMed |
| 41188903 | Leveraging the heterogeneity of the NK cell repertoire for the development of immunotherapies for acute leukemia. | J Transl Med | 2025 | https://conductscience.org/library/papers/41188903 | PubMed |
| 40882026 | Phenoscaping Reveals Multimodal γδ T-cell Cytotoxicity as a Strategy to Overcome Cancer Cell-Mediated Immunomodulation. | Cancer Res | 2025 | https://conductscience.org/library/papers/40882026 | PubMed |
| 40873276 | Pharmacodynamics and Pharmacokinetics of Ublituximab Compared with Other Anti-CD20 Monoclonal Antibodies for Multiple Sclerosis Treatment. | Curr Neuropharmacol | 2026 | https://conductscience.org/library/papers/40873276 | PubMed |
| 40728959 | FCGR2A-131R Is Associated with Lupus Nephritis Rather than Non-Lupus Nephritis SLE in an Indigenous African Caribbean Population. | Curr Issues Mol Biol | 2025 | https://conductscience.org/library/papers/40728959 | PubMed |
| 40682568 | Use of a Foamy-Virus Vector System to Produce an 'Off-the-Shelf' Fcγ-CR-T Cell Product for the Treatment of Haematological and Solid Tumour Malignancies. | Immunology | 2025 | https://conductscience.org/library/papers/40682568 | PubMed |
| 40402577 | High-affinity CD16A polymorphism associated with reduced risk ofsevere COVID-19. | JCI Insight | 2025 | https://conductscience.org/library/papers/40402577 | PubMed |
| 40332717 | Characterization of Biosimilar Monoclonal Antibodies and Their Reference Products Approved in Japan to Reveal the Quality Characteristics in Post-approval Phase. | BioDrugs | 2025 | https://conductscience.org/library/papers/40332717 | PubMed |
| 40274283 | CLN-619, a MICA/B monoclonal antibody that promotes innate immune cell-mediated antitumor activity. | J Immunother Cancer | 2025 | https://conductscience.org/library/papers/40274283 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| FCGR3A | 2214 | Swiss-Prot's references | https://conductscience.org/library/genes/2214 | NCBI Gene |
| IGHG3 | 3502 | PubTator's text mining | https://conductscience.org/library/genes/3502 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/9242542
GET https://conductscience.org/api/papers/v1/9242542/cited_by?page=2